EBioMedicine (Oct 2023)
Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathiesResearch in context
- Valérie Leclair,
- Angeles S. Galindo-Feria,
- Simon Rothwell,
- Olga Kryštůfková,
- Sepehr Sarrafzadeh Zargar,
- Herman Mann,
- Louise Pyndt Diederichsen,
- Helena Andersson,
- Martin Klein,
- Sarah Tansley,
- Lars Rönnblom,
- Kerstin Lindblad-Toh,
- Ann-Christine Syvänen,
- Marie Wahren-Herlenius,
- Johanna K. Sandling,
- Neil McHugh,
- Janine A. Lamb,
- Jiri Vencovský,
- Hector Chinoy,
- Marie Holmqvist,
- Matteo Bianchi,
- Leonid Padyukov,
- Ingrid E. Lundberg,
- Lina-Marcela Diaz-Gallo,
- Matteo Bianchi,
- Sergey V. Kozyrev,
- Johanna K. Sandling,
- Lars Rönnblom,
- Maija-Leena Eloranta,
- Ann-Christine Syvänen,
- Dag Leonard,
- Johanna Dahlqvist,
- Maria Lidén,
- Argyri Mathioudaki,
- Jennifer RS. Meadows,
- Jessika Nordin,
- Gunnel Nordmark,
- Ingrid E. Lundberg,
- Antonella Notarnicola,
- Leonid Padyukov,
- Anna Tjärnlund,
- Maryam Dastmalchi,
- Daniel Eriksson,
- Øyvind Molberg,
- Helena Andersson,
- Kerstin Lindblad-Toh,
- Fabiana H.G. Farias,
- Marie Wahren-Herlenius,
- Awat Jalal,
- Balsam Hanna,
- Helena Hellström,
- Tomas Husmark,
- Åsa Häggström,
- Anna Svärd,
- Thomas Skogh,
- Louise Pyndt Diederichsen,
- Janine A. Lamb,
- Simon Rothwell,
- Hector Chinoy,
- Robert G. Cooper,
- Kerstin Lindblad-Toh,
- Gerli Rosengren Pielberg,
- Anna Lobell,
- Åsa Karlsson,
- Eva Murén,
- Kerstin M. Ahlgren,
- Lars Rönnblom,
- Maija-Leena Eloranta,
- Göran Andersson,
- Nils Landegren,
- Olle Kämpe,
- Peter Söderkvis
Affiliations
- Valérie Leclair
- Clinical Epidemiology Division, Department Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Division of Rheumatology, Jewish General Hospital Lady Davis Institute, Montreal, Canada; Corresponding author. Karolinska Institutet, Clinical Epidemiology Division MedS, Karolinska Hospital T2, SE-171 76, Stockholm, Sweden.
- Angeles S. Galindo-Feria
- Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
- Simon Rothwell
- Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
- Olga Kryštůfková
- Institute of Rheumatology and Department of Rheumatology, 1st Medical Faculty, Charles University, Prague, Czech Republic
- Sepehr Sarrafzadeh Zargar
- Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
- Herman Mann
- Institute of Rheumatology and Department of Rheumatology, 1st Medical Faculty, Charles University, Prague, Czech Republic
- Louise Pyndt Diederichsen
- Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Department of Rheumatology, Odense University Hospital, Odense, Denmark
- Helena Andersson
- Department of Rheumatology, Oslo University Hospital, Oslo, Norway
- Martin Klein
- Institute of Rheumatology and Department of Rheumatology, 1st Medical Faculty, Charles University, Prague, Czech Republic
- Sarah Tansley
- Department of Life Sciences, University of Bath, Bath, United Kingdom
- Lars Rönnblom
- Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden
- Kerstin Lindblad-Toh
- Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden; Broad Institute of MIT and Harvard, Cambridge, MA, Unite States of America
- Ann-Christine Syvänen
- Science for Life Laboratory, Uppsala University, Department of Medical Sciences, Molecular Precision Medicine, Uppsala, Sweden
- Marie Wahren-Herlenius
- Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Norway
- Johanna K. Sandling
- Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden
- Neil McHugh
- Department of Life Sciences, University of Bath, Bath, United Kingdom
- Janine A. Lamb
- Epidemiology and Public Health Group, Faculty of Biology, Medicine and Health, University of Manchester, United Kingdom
- Jiri Vencovský
- Institute of Rheumatology and Department of Rheumatology, 1st Medical Faculty, Charles University, Prague, Czech Republic
- Hector Chinoy
- Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, United Kingdom; Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
- Marie Holmqvist
- Clinical Epidemiology Division, Department Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
- Matteo Bianchi
- Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
- Leonid Padyukov
- Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
- Ingrid E. Lundberg
- Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
- Lina-Marcela Diaz-Gallo
- Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Corresponding authors. CMM Foundation Karolinska University Hospital L8:04, SE-171 76, Stockholm, Sweden.
- Matteo Bianchi
- Sergey V. Kozyrev
- Johanna K. Sandling
- Lars Rönnblom
- Maija-Leena Eloranta
- Ann-Christine Syvänen
- Dag Leonard
- Johanna Dahlqvist
- Maria Lidén
- Argyri Mathioudaki
- Jennifer RS. Meadows
- Jessika Nordin
- Gunnel Nordmark
- Ingrid E. Lundberg
- Antonella Notarnicola
- Leonid Padyukov
- Anna Tjärnlund
- Maryam Dastmalchi
- Daniel Eriksson
- Øyvind Molberg
- Helena Andersson
- Kerstin Lindblad-Toh
- Fabiana H.G. Farias
- Marie Wahren-Herlenius
- Awat Jalal
- Balsam Hanna
- Helena Hellström
- Tomas Husmark
- Åsa Häggström
- Anna Svärd
- Thomas Skogh
- Louise Pyndt Diederichsen
- Janine A. Lamb
- Simon Rothwell
- Hector Chinoy
- Robert G. Cooper
- Kerstin Lindblad-Toh
- Gerli Rosengren Pielberg
- Anna Lobell
- Åsa Karlsson
- Eva Murén
- Kerstin M. Ahlgren
- Lars Rönnblom
- Maija-Leena Eloranta
- Göran Andersson
- Nils Landegren
- Olle Kämpe
- Peter Söderkvis
- Journal volume & issue
-
Vol. 96
p. 104804
Abstract
Summary: Background: In patients with idiopathic inflammatory myopathies (IIM), autoantibodies are associated with specific clinical phenotypes suggesting a pathogenic role of adaptive immunity. We explored if autoantibody profiles are associated with specific HLA genetic variants and clinical manifestations in IIM. Methods: We included 1348 IIM patients and determined the occurrence of 14 myositis-specific or –associated autoantibodies. We used unsupervised cluster analysis to identify autoantibody-defined subgroups and logistic regression to estimate associations with clinical manifestations, HLA-DRB1, HLA-DQA1, HLA-DQB1 alleles, and amino acids imputed from genetic information of HLA class II and I molecules. Findings: We identified eight subgroups with the following dominant autoantibodies: anti-Ro52, -U1RNP, -PM/Scl, -Mi2, -Jo1, -Jo1/Ro52, -TIF1γ or negative for all analysed autoantibodies. Associations with HLA-DRB1∗11, HLA-DRB1∗15, HLA-DQA1∗03, and HLA-DQB1∗03 were present in the anti-U1RNP-dominated subgroup. HLA-DRB1∗03, HLA-DQA1∗05, and HLA-DQB1∗02 alleles were overrepresented in the anti-PM/Scl and anti-Jo1/Ro52-dominated subgroups. HLA-DRB1∗16, HLA-DRB1∗07 alleles were most frequent in anti-Mi2 and HLA-DRB1∗01 and HLA-DRB1∗07 alleles in the anti-TIF1γ subgroup. The HLA-DRB1∗13, HLA-DQA1∗01 and HLA-DQB1∗06 alleles were overrepresented in the negative subgroup. Significant signals from variations in class I molecules were detected in the subgroups dominated by anti-Mi2, anti-Jo1/Ro52, anti-TIF1γ, and the negative subgroup. Interpretation: Distinct HLA class II and I associations were observed for almost all autoantibody-defined subgroups. The associations support autoantibody profiles use for classifying IIM which would likely reflect underlying pathogenic mechanisms better than classifications based on clinical symptoms and/or histopathological features. Funding: See a detailed list of funding bodies in the Acknowledgements section at the end of the manuscript.